Table 2.
Adjusted Differences in high-value and low-value primary care for respondents aged 18 years and older cared for by certified PCMH and non-PCMH providers.
| PCMH | Non-PCMH | ||||||
| Type of primary care∗ | No. | Estimates % (95% CI) | No. | Estimates % (95% CI) | Difference, % (95% CI)† | P‡ | Adjusted§P |
| High-value care | |||||||
| Diabetes care composite | 440 | 81.4 (75.1–87.7) | 627 | 83.2 (78.6–87.7) | −1.8 (−10.0 to 6.5) | .67 | .90 |
| HbA1c | 440 | 55.5 (47.8–63.1) | 627 | 54.7 (48.5–61.0) | 0.7 (−10.0 to 11.4) | .90 | .90 |
| Foot examination | 440 | 68.6 (61.7–75.4) | 627 | 65.5 (59.2–71.8) | 3.1 (−7.2 to 13.3) | .56 | .90 |
| Eye examination | 440 | 62.3 (56.3–68.4) | 627 | 61.5 (55.6–67.4) | 0.8 (−8.1 to 9.8) | .86 | .90 |
| Cancer screening composite | 1795 | 77.5 (73.7–81.4) | 2195 | 76.9 (74.1–79.6) | 0.6 (−4.0 to 5.3) | .79 | .90 |
| Cervical cancer Screening | 932 | 86.4 (82.3–90.4) | 1042 | 86.9 (83.5–90.2) | −0.5 (−5.8 to 4.8) | .85 | .90 |
| Breast cancer Screening | 668 | 81.6 (76.3–86.9) | 820 | 81.1 (77.1–85.2) | 0.5 (−6.6 to 7.5) | .90 | .90 |
| Colorectal cancer Screening | 1200 | 73.9 (69.1–78.7) | 1531 | 72.6 (69.1–76.1) | 1.3 (−4.5 to 7.0) | .67 | .90 |
| Diagnostic and preventive testing/care composite | 2540 | 98.2 (97.6–98.8) | 3208 | 97.0 (96.2–97.9) | 1.1 (0.1 to 2.2) | .03 | .46 |
| Cholesterol measurement | 2061 | 98.2 (97.6–98.8) | 2656 | 96.7 (95.7–97.7) | 1.5 (0.3 to 2.6) | .01 | .40 |
| Blood pressure measurement | 2540 | 99.3 (98.8–99.7) | 3208 | 98.8 (98.4–99.2) | 0.5 (−0.1 to 1.0) | .14 | .72 |
| Influenza vaccine | 2540 | 57.0 (53.6–60.4) | 3208 | 54.8 (51.7–57.9) | 2.2 (−2.2 to 6.7) | .33 | .85 |
| Routine checkup | 2540 | 87.7 (85.5–90.0) | 3208 | 87.2 (85.4–89.0) | 0.5 (−2.2 to 3.2) | .71 | .90 |
| Dental checkup | 2340 | 47.6 (43.7–51.6) | 2929 | 46.8 (43.2–50.5) | 0.8 (−4.5 to 6.0) | .78 | .90 |
| Counseling composite | 1918 | 67.2 (64.2–70.1) | 2440 | 65.0 (62.2–67.8) | 2.2 (−1.9 to 6.4) | .30 | .84 |
| Exercise counseling | 1788 | 65.4 (62.0–68.7) | 2306 | 63.7 (60.9–66.5) | 1.7 (−2.7 to 6.1) | .46 | .90 |
| Smoking cessation counseling | 358 | 75.9 (67.7–84.1) | 442 | 74.0 (67.9–80.1) | 2.0 (−8.2 to 12.1) | .71 | .90 |
| Medical treatment composite | 985 | 32.2 (27.2–37.2) | 1369 | 36.7 (31.0–42.3) | −4.4 (−12.2 to 3.3) | .26 | .84 |
| Anticoagulation for atrial fibrillation | 116 | 49.5 (38.8–60.1) | 150 | 60.8 (51.3–70.4) | −11.4 (−25.1 to 2.3) | .10 | .80 |
| Salicylates and/or platelet aggregation inhibitors for CAD/MI | 452 | 14.6 (8.9–20.2) | 637 | 13.4 (7.7–19.2) | 1.1 (−7.0 to 9.2) | .79 | .90 |
| Beta blocker for CAD/MI | 452 | 59.3 (51.6–67.0) | 637 | 67.7 (60.5–74.9) | −8.4 (−19.3 to 2.4) | .13 | .79 |
| ACEi/ARB for diabetes & hypertension | 489 | 64.3 (56.6–72.0) | 721 | 63.2 (56.4–70.0) | 1.1 (−8.9 to 11.2) | .83 | .90 |
| Antiplatelet for CVA | 164 | 17.4 (10.0–24.8) | 224 | 28.4 (19.8–36.9) | −11.0 (−21.6 to −0.3) | .04 | .46 |
| Low-value care | |||||||
| Cancer screening composite | 470 | 47.1 (40.1–54.2) | 713 | 42 (36.2–47.9) | 5.1 (−4.1 to 14.4) | .28 | .84 |
| Cervical cancer screening in women aged 65 + | 384 | 42.2 (34.4–50.0) | 544 | 38.1 (32.1–44.2) | 4.1 (−5.7 to 13.8) | .41 | .90 |
| Colorectal cancer screening in adults aged 75 + | 260 | 22.5 (14.3–30.6) | 414 | 17.7 (12.4–22.9) | 4.8 (−3.8 to 13.4) | .27 | .84 |
| Prostate cancer screening in men aged 75 + | 86 | 33.9 (21.6–46.2) | 169 | 37.9 (28.6–47.2) | −4 (−20.4 to 12.4) | .63 | .90 |
| Medical treatment composite | 1501 | 11.2 (8.8–13.5) | 2048 | 12.4 (10.1–14.6) | −1.2 (−4.4 to 2.0) | .46 | .90 |
| Anxiolytics/sedatives/ hypnotics in adults 65 + | 834 | 7.6 (5.1–10.1) | 1219 | 8.8 (6.6–11.1) | −1.2 (−4.8 to 2.3) | .50 | .90 |
| Benzodiazepine for depression | 273 | 21.3 (15.2–27.3) | 346 | 25.8 (19.4–32.1) | −4.5 (−12.8 to 3.9) | .29 | .84 |
| NSAID use for hypertension/heart failure/kidney disease | 908 | 10.1 (6.9–13.2) | 1208 | 10.8 (8.1–13.6) | −0.8 (−4.9 to 3.3) | .71 | .90 |